AIM ImmunoTech Announces Trading Under the Ticker AIMI on the Pink Open Market

Company Overview - AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19 [3] - The company's lead product is Ampligen® (rintatolimod), a first-in-class investigational drug that acts as a dsRNA and highly selective TLR3 agonist immuno-modulator, showing broad spectrum activity in clinical trials [3] Recent Developments - As of April 7, 2025, AIM's common stock is trading under the ticker AIMI on the Pink Open Market [1] - A special meeting regarding a reverse stock split is scheduled for April 30, 2025 [1] - Additional information can be found in AIM's Definitive Proxy Statement filed on April 2, 2025 [2]